



Anti-infective proteins in breast milk and asthma-associated phenotypes during early childhood

Journal:	<i>Pediatric Allergy and Immunology</i>
Manuscript ID:	PAI-14-O-0162.R2
Manuscript Type:	Original
Date Submitted by the Author:	n/a
Complete List of Authors:	Zhang, Guicheng; Curtin University, School of Public Health Lai, Ching-tat; The University of Western Australia, School of Chemistry and Biochemistry, Faculty of Science Hartmann, Peter; The University of Western Australia, School of Chemistry and Biochemistry, Faculty of Science Oddy, Wendy; Telethon Kids Institute, Population Sciences; The University of Western Australia, Kusel, Merci; Telethon Kids Institute, Clinical Sciences; The University of Western Australia, Sly, Peter; The University of Queensland, Queensland Children's Medical Research Institute Holt, Patrick; Telethon Kids Institute, Cell Biology; The University of Western Australia,
Topics of paper:	nutrition: breast milk, asthma: infectious diseases, asthma: pathophysiology, epidemiology: Epidemiology of asthma, epidemiology: Epidemiology of allergies



1 Anti-infective proteins in breast milk and asthma-associated phenotypes during early childhood

2

3

4 Zhang, Guicheng*¹; Lai, Ching Tat*²; Hartmann, Peter²; Oddy, Wendy H³; Kusel, Merci MH³; Sly,
5 Peter D⁴; Holt Patrick G^{3,4}

6 * contribute equally

7

8

9 ¹ School of Public Health, Curtin University, Perth, Western Australia, Australia10 ² School of Chemistry and Biochemistry, Faculty of Science, The University of Western Australia,
11 Perth, Western Australia, Australia12 ³ Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia13 ⁴ University of Queensland, Queensland Children's Medical Research Institute, Brisbane, Queensland,
14 Australia

15

16

17 Running title: Breast milk proteins and risk for atopy/asthma

18

19

20 Corresponding Authors:

21

22 Prof Patrick G Holt

23 Professor P G Holt

24 Division of Cell Biology

25 Telethon Kids Institute

26 PO Box 855

27 West Perth WA 6872 Australia

28

29 Tel: +61 8 9489 7838

30 Email: Patrick.Holt@telethonkids.org.au

31 Marina.Stubbs@telethonkids.org.au

32

33 Dr Guicheng Zhang, School of Public Health, Curtin University

34 Email: brad.zhang@curtin.edu.au

35

36 Word Count; 3022

37

38 **Abstract**

39 **Background**

40 The impact of breastmilk feeding on susceptibility to asthma in childhood is highly controversial, due
41 in part to failure of the majority of studies in the area to adequately account for key confounders
42 exemplified by respiratory infection history, plus the effects of recall bias.

43

44 **Methods**

45 As part of a prospective cohort study on the role of respiratory infections in asthma development in
46 high-risk children, we measured the concentration of a panel of anti-infective proteins in maternal milk
47 samples, and analysed associations between these and subsequent atopy-, infection- and asthma-related
48 outcomes prospectively to age 10 years.

49

50 **Results**

51 We observed significant but transient inverse associations between the concentration of milk proteins
52 and susceptibility to upper respiratory infections in year 1 only, and parallel but positive transient
53 associations with early lower respiratory infections and atopy. No associations were seen with asthma-
54 related outcomes.

55

56 **Conclusions**

57 Breast milk feeding may influence the expression of inflammatory symptoms associated with
58 respiratory infections and atopy in early life but these effects appear to be inconsistent and transient.
59 The heterogeneous nature of breastfeeding effects suggests it may influence systemic
60 immunoinflammatory function at several different levels.

61

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. Pediatric Allergy and Immunology. 25 (6): pp. 544-551.

62

63

64 Keywords: atopy, breast feeding, infancy, respiratory infection, wheezing, IgA, lysozyme, lactoferrin

65

66

67

For Peer Review

68 Introduction

69

70 Breastfeeding is widely acknowledged to have protective effects against a range of health problems in
71 infancy and childhood, as well as reducing risk for some chronic diseases that manifest in later life¹.
72 Until comparatively recently, allergy-associated syndromes including atopic asthma were paramount
73 amongst the list of diseases reportedly susceptible to the protective effects of breastfeeding,^{2,3} and
74 recommendations for exclusive breastfeeding for the first 6 months of life have been a prominent
75 feature of many official guidelines aimed at allergy prevention^{4,5}.

76

77 However, a growing body of information derived from birth cohort studies has questioned the validity
78 of this paradigm. The relevant findings include observations linking early introduction of allergenic
79 foods with decreased risk of subsequent food allergy^{6,7}, the lack of evidence from the large scale
80 ISAAC study for any protective effect of exclusive breastfeeding against eczema⁸, and suggestive
81 evidence that in certain populations breastfeeding may even *increase* long term risk for atopy and
82 asthma^{9,10}.

83

84 The relationship between breastfeeding and asthma/allergic disease risk remains highly controversial.
85 Complicating this debate is the growing realization that the majority of the available studies which
86 have shaped current opinions in this area suffer from methodological flaws that mitigate against
87 reaching firm conclusions^{9,11}. The protective effects of breastfeeding on infection and allergic
88 conditions are known to be largely derived from the proteins of human milk¹². Amongst the most
89 important are secretory immunoglobulin A (sIgA), lysozyme and lactoferrin which are major whey
90 proteins which are well known for their immune properties against a range of infections and diseases¹².

91 Together with other immune proteins in human milk, they assist infants to establish and strengthen
92 their immunity against infections and diseases later in life¹³.

93 Our aim in the present study was to ascertain whether these protein components of breast milk have
94 demonstrable activity in relation to protection of children against asthma and allergy. The findings
95 reported below are derived from a subgroup of subjects from the Perth CAS cohort¹⁴⁻¹⁷, the design of
96 which enables examination of this issue from a unique perspective. Notably, this study had a primary
97 focus on respiratory infection and as such included physician verification and clinical assessment of all
98 parent-reported putative infection events within the first 5 years of life. Moreover, the subgroup from
99 this cohort utilized for these analyses was restricted to children whose mothers provided breast milk
100 samples, and the study mothers were closely monitored and supported by the clinical team including
101 collection and analysis of breast milk samples at 6 weeks and 6 months post partum. In addition to
102 physician-monitoring of each respiratory infection event in these children, objective assessment of
103 allergy-associated and asthma-associated clinical phenotypes was performed at 6mths and annually to
104 age 5 years, with additional followup at age 10 years. This approach enabled collection of a unique data
105 set for examination of the question of whether breast feeding influences allergy/asthma susceptibility
106 from a perspective not previously considered in detail i.e. whether differences in the concentration of
107 key protein constituents in milk (milk “quality”) were associated with variations in disease risk
108 amongst recipients. The milk constituents chosen for these analyses were secretory immunoglobulin A
109 (sIgA), lysozyme and lactoferrin, in addition to total protein.

110

111 **Methodology**

112 ***Subjects***

113 142 mother:infants pairs from the CAS cohort^{16,17} were included in the milk study. The cohort was
114 initiated in 1996 in the Perth metropolitan area, all subjects were enrolled antenatally and classified as
115 having an atopic family history based on a standard questionnaire and a positive doctor's diagnosis of
116 asthma, hay fever, or atopic dermatitis for 1 or both parents. The cohort has been follow up at 6 weeks,
117 6 months, 1, 2, 3, 4, 5 and 10 years with comprehensive assessment of allergic and asthmatic
118 phenotypes¹⁵⁻¹⁷.

119

120 Breastfeeding history was monitored through dietary questionnaire administered at the 6 week and 6
121 month visits and breast milk samples were collected at these visits. Infectious episodes were
122 prospectively recorded throughout the first 5 years with a daily parental diary; parents were trained to
123 summon the clinical team at every incidence of suspected respiratory infection, enabling symptom
124 verification during the ensuing home visits by the clinical team. Acute respiratory infections (ARIs)
125 were subclassified as lower respiratory infection (LRI), wheezy lower respiratory infection (wLRI) and
126 upper respiratory infection (URI) as detailed in the online supplement. Skin prick tests to a panel of
127 ingested and aero- allergens were performed at 6 months, 2 years, 5 and 10 years to define atopy. The
128 subjects were examined for eczema on each of the scheduled followup visits as well as during all home
129 visits for respiratory episodes during the first 5 years. Eczema was defined as doctor diagnosis of
130 eczema or atopic dermatitis experienced by child in last 12 months. Wheezing is the parental opinion of
131 whether child wheezed in last 12 months. Asthma was defined as wheeze during last 12 months (parent
132 opinion) plus Doctor diagnosis of asthma beyond the second birthday.

133

134 ***Protein measurements***

135 The milk samples were stored at -20°C after collection. Before biochemical analysis, thawed milk
136 samples were centrifuged at 10000 RPM for 10 minutes. The tube was sliced to remove the fat layer.
137 The sIgA, lysozyme, lactoferrin and total protein were assayed in the defatted milk.

138

139 Lysozyme in the samples was measured by a modification of Selsted & Martinez¹⁸. Lactoferrin and
140 sIgA in the samples was determined by ELISA¹⁹. Total protein was determined by a protein assay that
141 measured the binding of the protein dye (Bio-Rad) to the primarily basic and aromatic amino acid
142 residues of the proteins. Further assay details appear in the online supplement

143 *Statistical analysis*

144 Protein levels were log-transformed to have an approximately normal distribution. As the number of
145 infectious episodes such as URI and LRI was a count variable Poisson regression was employed to
146 investigate the associations between levels of milk proteins and the incidence of respiratory infections.
147 In order to examine the associations of breast milk proteins with binary outcomes such as atopy ,
148 eczema, wheezing and asthma we compared the levels of these between the two scenarios of these
149 binary outcomes using general linear models after adjusting for gender, passive smoking and number of
150 older siblings. All the analyses were conducted using IBM SPSS Statistics 20.

151

152 **Results**

153 In this subcohort there were initially 142 infants. Five infants who were partly fed with formula were
154 subsequently excluded from the analyses. Table 1 shows the characteristics of 137 children included in
155 the present study and the remaining children in the longitudinal cohorts. The children for this study
156 appeared to have lower prevalence of smoking exposure and childcare attendance at age 1, compared
157 with the remaining children. Table 2 shows prevalence of these conditions in the 137 children who
158 completed the study.

159

160 ***Levels of breast milk proteins***

161 Within individual milk donors, the concentrations of sIgA, lactoferrin, lysozyme and total protein
162 varied between breasts at both six weeks and six months of lactation (Table 3). The range in the
163 concentrations of sIgA, lactoferrin, lysozyme and total protein from each breast at both six weeks and
164 six months of lactation was large (Table 3). At six weeks of lactation, the mean concentrations of the
165 right and left breasts for sIgA were (0.67 ± 0.36 g/l), lactoferrin was (2.59 ± 1.58), lysozyme was ($0.07 \pm$
166 0.07 g/l) and total protein was (15.1 ± 12.87 g/l) respectively. At six months of lactation, the mean
167 concentrations of the right and left breasts for sIgA were (0.71 ± 0.40 g/l), lactoferrin was (2.13 ± 1.29),
168 lysozyme was (0.11 ± 0.11 g/l) and total protein was (12.1 ± 5.84 g/l) respectively. There were
169 significant changes in the concentration of sIgA, lactoferrin, lysozyme and total protein in milk from
170 both breasts, except sIgA (left breast only), between six weeks and six months of lactation (data not
171 shown). All subsequent analyses utilized mean data from two breasts for each mother in the study.

172

173 ***Atopy***

174 We investigated associations between the concentrations of breast milk proteins with atopy defined by
175 skin prick tests (SPT) at age 6 months, 2 and 5 years. We chose to measure atopy status at multiple
176 time points in light of our early demonstration¹⁴ that IgE production is commonly cyclical over time
177 during the preschool years. The levels of milk proteins in the study population are shown in Figure 1,
178 stratified by atopy outcomes in their offspring at these three time points. sIgA concentrations in milk
179 samples collected at 6 months were significantly higher ($p = 0.019$) in the mothers whose infants
180 developed atopy by this age, compared with mothers of infants without atopy (Fig 1a). The 6 month
181 lactoferrin levels were also significantly higher ($p = 0.022$) in this group (Fig 1c), as well as 6 week (p
182 $= 0.028$) and 6 month ($p = 0.009$) total protein levels (Fig 1d). Similar effects were observed with

8

183 respect to total protein levels in maternal milk samples (Fig 1d), which were significantly higher at
184 both 6 weeks ($p = 0.001$) and 6 months ($p = 0.012$) in mothers whose infants developed atopy by age 2.
185 It appeared that this relationship persisted up to outcome age 2 years but was lost by 5 years; additional
186 regression modeling of 10 year data also did not demonstrate significant associations between milk
187 protein content and atopy outcomes.

188

189 *Eczema*

190 Eczema was assessed at each followup of the cohort. We compared levels of individual breast milk
191 proteins in offspring with and without eczema at these time points after adjusting for gender, number of
192 older children and passive smoking, and results out to year 3 are shown in Table 4 (as above,
193 unadjusted data yielded similar results). Positive associations were observed between Lactoferrin
194 levels and eczema outcomes at 6 months and 1 and 3 years, but not beyond these time points (not
195 shown) with an exception that a marginal effect of milk lysozyme at 6 months on current eczema at age
196 10 was also observed. ($p=0.048$).

197

198 *Respiratory infections*

199 We assessed associations between levels of maternal milk proteins and risk in their offspring for
200 respiratory infections in the first 3 years, using Poisson regression models and adjusting for gender,
201 passive smoking and number of older siblings. Generally, the presence of high levels of anti-infective
202 proteins were associated with reduced frequency of URIs ($IRR < 1$) in the first two years of life
203 (Supplementary Table 1). sIgA levels were associated with a decreased risk for URIs in the first year
204 of life at a significance of $p = 0.035$ and 0.079 for milk samples collected at 6 weeks and 6 months,
205 respectively, and similarly for Lactoferrin levels in 6 month samples ($p=0.008$). With respect to year 2

206 URI outcomes, 6 week IgA and 6 month Lactoferrin levels were also significantly associated with a
207 decreased risk for URI ($p=0.005$ and 0.015 respectively). These associations diminished beyond year 2.

208

209 No associations were observed that were consistent with parallel milk-mediated protection against the
210 spread and/or intensification of infections in the lower respiratory tract. Instead, high levels of
211 Lactoferrin and/or Lysozyme in early milk samples were paradoxically associated with increased risk
212 for wheezing lower respiratory infections, but only during the first year of life (Supplementary Table
213 2).

214

215 *Wheezing and asthma*

216 Current wheezing was evaluated at each annual visit and asthma was defined at ages 3, 4, 5 and 10
217 years. No significant associations were found between the concentrations of breast milk proteins with
218 these phenotypes employing either adjusted or raw data utilized above (not shown). In followup
219 analyses we also tested multiple regression models in which qualitative and quantitative respiratory
220 tract infection history over the first two years of life were included as additional confounders, and again
221 could not identify any significant linkages between milk protein levels and asthma-associated
222 phenotypes (data not shown).

223

224 **Discussion**

225 The focus of studies in the CAS birth cohort is on identification of factors driving asthma pathogenesis
226 during childhood. Our previous investigations in this cohort have identified early allergic sensitization
227 and concomitant respiratory tract infections as major asthma risk factors¹⁶. These can operate
228 independently to drive asthma development, however the highest level of risk is observed in children
229 who experience both sensitization and respiratory tract infections concomitantly during this period¹⁴.

230 The initial diagnosis of asthma in the cohort was made at age 5 years¹⁶, but more recently it was shown
231 that these effects carry through to at least 10 years¹⁵. It is additionally noteworthy that the relevant
232 infections are those that spread to the lower respiratory tract and attain sufficient severity to trigger
233 symptoms of wheeze and/or fever, whereas infections that remain restricted to the upper respiratory
234 tract are benign in this context^{15,16}.

235

236 It is reasonable to consider breast milk intake as a potential factor that may modulate asthma risk in
237 CAS cohort subjects for a number of reasons, in particular (i) an earlier literature suggesting that breast
238 milk feeding can protect against allergic sensitization (e.g.³); (ii) the well established role of
239 breastfeeding in protecting infants against both enteric and respiratory infections²²; and (iii) the reports
240 from earlier observational studies linking exclusive breast feeding with reduced rates of subsequent
241 wheeze²³⁻²⁵.

242

243 These claims have biological plausibility at several levels. Notably, it has been established that innate
244 and adaptive immune functions in all infants are in a functionally quiescent state at birth²⁶⁻²⁸, and
245 mature postnatally in response to environmental microbial stimulation, especially from commensal
246 organisms in the gastrointestinal tract (reviewed^{29,30}) but also from common childhood infections (the
247 “Hygiene Hypothesis”³¹). However, as noted above, certain categories of severe respiratory infections
248 appear to have the opposite effects in relation to risk of asthma, likely due in part to direct
249 inflammatory damage to developing lung function extrinsic to any influence on immune system
250 maturation³².

251

252 The kinetics of postnatal immune maturation is sluggish in a significant subset of children at high risk
253 of developing atopy/asthma^{33,34}, and hence factors that modulate exposure to common and relatively

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

254 benign childhood infections, and/or patterns of colonization with commensal microflora, may influence
255 this process in ways that cannot be predicted. In this regard it is noteworthy that a growing literature
256 has implicated breast milk feeding as an important modulator of quantitative and qualitative aspects of
257 postnatal bacterial colonization of the GIT³⁵⁻³⁷.

258

259 These complexities may explain some of the disparities in the literature on relationships between breast
260 feeding and future atopy/asthma outcomes, and likewise some of the apparent contradictions in our
261 findings above from the CAS cohort. Notably, a clear finding in these subjects was the inverse
262 association between levels of the anti-infectives IgA and Lactoferrin in milk and risk for upper
263 respiratory infections in year 1, which extended into year 2 (Table 4). However, these protective
264 effects were not seen with respect to the lower respiratory tract, and instead levels of milk proteins (in
265 this case Lactoferrin and Lysozyme) were positively associated with risk for wheezing infections
266 (Table 5). Similar positive relationships were observed between levels of milk proteins and early
267 atopic outcomes measured as either SPT reactivity (Figs 1 and 2) or eczema (Table 3; Fig 3); in both
268 cases these effects were transient and were not generally seen beyond 2 years. In this regard we have
269 previously reported that increased amounts of omega-3 fatty acids in maternal milk at 6 weeks
270 protected against eczema at 6 months, but this protection did not continue to later ages³⁸.

271

272 The dichotomous nature of our findings cannot be fully explained, but some possibilities can be
273 considered. Firstly, breast milk feeding-associated protection against relatively mild URI at/around the
274 time of infancy is not unexpected and is consistent with what is known re the anti-infective properties
275 of maternal milk mediated via direct effects of anti-microbial molecules on incoming pathogens.

276

277 However the reasons for dissociation between these URI effects and those relating to susceptibility to
278 atopy and/or the spread of infections to the LRI are unclear. Possible explanations include (i) these
279 severe LRI events may reflect higher pathogen loads that are beyond the range that is potentially
280 controllable by milk-born anti-infectives; (ii) resistance to infection spread/intensification and to atopic
281 sensitization in infants may depend upon defence mechanisms that are discrete from those that protect
282 against URI, in particular cellular immune mechanisms that are reliant upon “endogenous” maturation-
283 inducing microbial signals, particularly from GIT commensals, colonization with which is likely
284 influenced by milk-born anti-infectives. However it is not feasible to directly test these possibilities
285 with the available data.

286

287 The most clearcut finding in our study is the lack of discernible milk protein quality-associated effects
288 on asthma-related outcomes that persist beyond early childhood. It is pertinent to reiterate that these
289 outcomes have been shown to be highly sensitive to early history of both atopy and LRI in this
290 cohort¹⁴⁻¹⁶, which as noted above are transiently influenced by breast milk quality, but apparently not to
291 a degree which influences subsequent susceptibility to asthma. Our findings are thus consistent with the
292 growing body of evidence suggesting that the long-term benefits of breast milk feeding in relation to
293 these atopy- and asthma-associated phenotypes are limited⁶⁻¹⁰ but we cannot completely exclude effects
294 based on our study because our sample size is small. We have described all statistical analyses carried
295 out and did not make multiple test corrections because (i) they can be overly conservative and may
296 inflate type II errors and (ii) our analyses were based on an *a priori* hypothesis³⁹.

297

298 In conclusion it is relevant to acknowledge the limitations of this study. Firstly regarding the lack of
299 association between wheezing/asthma and levels of milk proteins we acknowledge the possible type II
300 errors due to relatively small sample size, which also precluded further sub-group analysis on the

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

301 effects of milk proteins on other outcomes. However, this is a longitudinal cohort with wheezing
302 phenotypes comprehensively investigated, which is superior to a cross-sectional study. There were
303 strong correlations between levels of individual proteins and the total milk proteins. We, therefore,
304 could not further clarify the effects of individual proteins in this cohort. Additionally, while unlike
305 previous investigations we have been able to include comprehensive data relating to the potential
306 confounding effects of infection history in regression models of milk-related effects on asthma-
307 associated outcomes, this remains a relatively small study, and larger sample sizes with greater
308 statistical power may be required to finally resolve this issue. Also, our study population are all at high
309 genetic risk for atopy/asthma and thus representative of 40-45% of the pediatric population, and
310 accordingly are not representative of the general population.

311

312 **Figure legends:**

313 Figure 1 The adjusted geometric means (g/l) and 95% confidence intervals of milk proteins collected at
314 6 weeks (6w) and 6 months (6m), stratified by atopy assessed using skin prick tests at 6 months, 2 and
315 5 years of age; General linear models were employed for the analyses with gender, passive smoking
316 and number of older children adjusted for; a: sIgA, b: Lysozyme, c: Lactoferrin, and d: Total Protein;
317 ■ : Solid square, children with atopy (yes) △ : Open triangle, children without atopy (no)

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336 **References**

337

338 1. Dieterich CM, Felice JP, O'Sullivan E, Rasmussen KM. Breastfeeding and health outcomes for
339 the mother-infant dyad. *Pediatr Clin North Am* 2013;60:31-48.

340 2. Oddy WH, de Klerk NH, Sly PD, Holt PG. The effects of respiratory infections, atopy, and
341 breastfeeding on childhood asthma. *European Respiratory Journal* 2002;19:899-905.

342 3. Oddy WH, Holt PG, Sly PD, et al. Association between breast feeding and asthma in 6 year old
343 children: findings of a prospective birth cohort study. *BMJ (Clinical research ed)* 1999;319:815-9.

344 4. NHMRC. Eat for Health: Australian Dietary Guidelines. In: Australia NHMRC, ed.: National
345 Health and Medical Research Council of Australia; 2013:36.

346 5. Kramer MS, Kakuma R. The optimal duration of exclusive breastfeeding: a systematic review.
347 *Adv Exp Med Biol* 2004;554:63-77.

348 6. Du Toit G, Katz Y, Sasieni P, et al. Early consumption of peanuts in infancy is associated with
349 a low prevalence of peanut allergy. *J Allergy Clin Immunol* 2008;122:984-91.

350 7. Koplin JJ, Osborne NJ, Wake M, et al. Can early introduction of egg prevent egg allergy in
351 infants? A population-based study. *J Allergy Clin Immunol* 2010;126:807-13.

352 8. Flohr C, Nagel G, Weinmayr G, et al. Lack of evidence for a protective effect of prolonged
353 breastfeeding on childhood eczema: lessons from the International Study of Asthma and Allergies in
354 Childhood (ISAAC) Phase Two. *Br J Dermatol* 2011;165:1280-9.

355 9. Sears MR, Greene JM, Willan AR, et al. Long-term relation between breastfeeding and
356 development of atopy and asthma in children and young adults: a longitudinal study. *Lancet*
357 2002;360:901-7.

358 10. Wright AL, Holberg CJ, Taussig LM, Martinez FD. Factors influencing the relation of infant
359 feeding to asthma and recurrent wheeze in childhood. *Thorax* 2001;56:192-7.

- 360 11. Matheson MC, Allen KJ, Tang ML. Understanding the evidence for and against the role of
361 breastfeeding in allergy prevention. *Clin Exp Allergy* 2012;42:827-51.
- 362 12. Lonnerdal B. Bioactive proteins in human milk: mechanisms of action. *The Journal of*
363 *pediatrics* 2010;156:S26-30.
- 364 13. Walker A. Breast milk as the gold standard for protective nutrients. *The Journal of pediatrics*
365 2010;156:S3-7.
- 366 14. Holt P, Rowe J, Kusel M, et al. Towards improved prediction of risk for atopy and asthma
367 amongst preschoolers: a prospective cohort study. *J Allergy Clin Immunol* 2010;125:645-51.
- 368 15. Kusel M, Keadze T, Johnston S, Holt P, Sly P. Febrile respiratory illnesses in infancy and
369 atopy are risk factors for persistent asthma and wheeze. *European Respiratory Journal* 2012;39:876-82.
- 370 16. Kusel MM, de Klerk NH, Keadze T, et al. Early-life respiratory viral infections, atopic
371 sensitization, and risk of subsequent development of persistent asthma. *Journal of Allergy and Clinical*
372 *Immunology* 2007;119:1105-10.
- 373 17. Kusel MMH, de Klerk NH, Holt PG, Keadze T, Johnston SL, Sly PD. Role of respiratory
374 viruses in acute upper and lower respiratory tract illness in the first year of life - A birth cohort study.
375 *Pediatric Infectious Disease Journal* 2006;25:680-6.
- 376 18. Selsted ME, Martinez RJ. A simple and ultrasensitive enzymatic assay for the quantitative
377 determination of lysozyme in the picogram range. *Anal Biochem* 1980;109:67-70.
- 378 19. Tijssen P. Laboratory techniques in biochemistry and molecular biology. In: Burdon RHavK,
379 P.H., ed. *Practice and theory of immunoessays*. New York: Elsevier; 1985.
- 380 20. Atwood CS, Hartmann PE. Collection of fore and hind milk from the sow and the changes in
381 milk composition during suckling. *J Dairy Res* 1992;59:287-98.
- 382 21. Hambraeus L, Lonnerdal B, Forsum E, Gebre-Medhin M. Nitrogen and protein components of
383 human milk. *Acta Paediatr Scand* 1978;67:561-5.

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

- 384 22. Paramasivam K, Michie C, Opara E, Jewell AP. Human breast milk immunology: a review. *Int*
385 *J Fertil Womens Med* 2006;51:208-17.
- 386 23. Aberg N, Engstrom I, Lindberg U. Allergic diseases in Swedish school children. *Acta Paediatr*
387 *Scand* 1989;78:246-52.
- 388 24. Chandra RK. Five-year follow-up of high-risk infants with family history of allergy who were
389 exclusively breast-fed or fed partial whey hydrolysate, soy, and conventional cow's milk formulas. *J*
390 *Pediatr Gastroenterol Nutr* 1997;24:380-8.
- 391 25. Kaufman HS, Frick OL. The development of allergy in infants of allergic parents: a prospective
392 study concerning the role of heredity. *Ann Allergy* 1976;37:410-5.
- 393 26. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. *Nat Rev*
394 *Immunol* 2007;7:379-90.
- 395 27. Siegrist CA. Vaccination in the neonatal period and early infancy. *Int Rev Immunol*
396 2000;19:195-219.
- 397 28. Holt PG. Postnatal maturation of immune competence during infancy and childhood [Review].
398 *Pediatric Allergy and Immunology* 1995;6:59-70.
- 399 29. Holt PG. Environmental factors and primary T-cell sensitization to inhalant allergens in
400 infancy: reappraisal of the role of infections and air pollution [Review]. *Pediatric Allergy and*
401 *Immunology* 1995;6:1-10.
- 402 30. Rook GA, Stanford JL. Give us this day our daily germs. *Immunology Today* 1998;19:113-6.
- 403 31. Strachan DP. Hay fever, hygiene, and household size. *Br Med J* 1989;299:1259-60.
- 404 32. Holt PG, Sly PD. Viral Infections and atopy in asthma pathogenesis: new rationales for asthma
405 prevention and treatment. *Nature Medicine* 2012;18:726-35.
- 406 33. Holt PG, Clough JB, Holt BJ, et al. Genetic 'risk' for atopy is associated with delayed postnatal
407 maturation of T-cell competence. *Clinical and Experimental Allergy* 1992;22:1093-9.

- 408 34. Prescott SL, Macaubas C, Smallacombe T, Holt BJ, Sly PD, Holt PG. Development of allergen-
409 specific T-cell memory in atopic and normal children. *Lancet* 1999;353:196-200.
- 410 35. Favier CF, de Vos WM, Akkermans AD. Development of bacterial and bifidobacterial
411 communities in feces of newborn babies. *Anaerobe* 2003;9:219-29.
- 412 36. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in
413 patients with recurrent malignant glioma. *J Clin Oncol* 2000;18:646-50.
- 414 37. Kleessen B, Bunke H, Tovar K, Noack J, Sawatzki G. Influence of two infant formulas and
415 human milk on the development of the faecal flora in newborn infants. *Acta Paediatr Scand*
416 1995;84:1347-56.
- 417 38. Oddy WH, Pal S, Kusel MM, et al. Atopy, eczema and breast milk fatty acids in a high-risk
418 cohort of children followed from birth to 5 yr. *Pediatr Allergy Immunol* 2006;17:4-10.
- 419 39. Perneger TV. What's wrong with Bonferroni adjustments. *BMJ (Clinical research ed)*
420 1998;316:1236-8.

421

422

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

Table 1 The comparison of the 137 children and the remaining children in the longitudinal cohort

	137 children for milk protein analysis n/N (%)	Remaining children n/N (%)	p
Males	83/137 (60.6)	63/124 (50.8)	0.11
Maternal atopy history	106/135 (78.5)	71/89 (79.8)	0.82
Paternal atopy history	92/135 (68.1)	59/89 (66.3)	0.77
Exposure to passive smoking at age 1	19/134 (14.2)	25/93 (26.9)	0.017
Exposure to passive smoking at age 5	13/122 (10.7)	17/76 (22.4)	0.025
Childcare attendance at age 1	32/134 (23.9)	34/93 (36.6)	0.039
Childcare attendance at age 5	52/129 (40.3)	45/91 (49.5)	0.18
Asthma at age 5	23/122 (18.9)	12/76 (15.8)	0.58

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

Table 2 Allergic phenotypes in the 137 children included in the study

	6 months		1 year		2 year		3 years		4 years		5 years		10 years	
	n/N	%	n/N	%	n/N	%	n/N	%	n/N	%	n/N	%	n/N	%
Atopy	28/131	21.4	-	-	58/131	44.3	-	-	-	-	47/119	39.5	69/84	82.1
Eczema	68/137	49.6	52/137	38.0	48/131	36.6	37/127	29.1	37/125	29.6	35/122	28.7	25/97	25.8
Wheezing	-	-	46/137	33.6	40/131	30.5	38/127	29.9	33/125	26.4	36/122	29.5	11/96	11.5
Asthma	-	-	-	-	-	-	-	-	-	-	23/122	18.9	14/95	14.7

n: number children with the condition; N: total number of children; Atopy: Skin prick test positive to one or more allergens (wheal size>2 mm); Eczema: Doctor diagnosis of eczema or atopic dermatitis experienced by child in last 12 months; Wheezing: parental opinion of whether child wheezed in last 12 months; Asthma: wheeze during last 12 months plus Doctor diagnosis of asthma beyond the second birthday

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

Table 3 Concentrations (g/l) of milk proteins

		At 6 weeks			At 6 months			
		n	Mean	SD	n	Mean	SD	p
sIgA	Right	135	0.709	0.443	134	0.712	0.479	0.67
	Left	136	0.620	0.390	133	0.710	0.475	
	Average	134	0.669	0.358	132	0.711	0.400	
Lysozyme	Right	136	0.077	0.088	133	0.099	0.102	<0.001
	Left	135	0.071	0.078	131	0.127	0.154	
	Average	134	0.074	0.071	131	0.113	0.110	
Lactoferrin	Right	134	2.670	1.861	132	2.326	1.874	<0.001
	Left	135	2.526	1.896	130	1.900	1.363	
	Average	133	2.598	1.579	130	2.126	1.289	
Total protein	Right	136	14.867	8.655	132	12.696	7.107	<0.001
	Left	135	15.497	21.248	129	11.310	6.229	
	Average	134	15.145	12.873	129	12.056	5.842	

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

Table 4 Adjusted geometric means (g/l) and 95% confidence intervals of milk proteins collected at 6 weeks (6w) and 6 months (6m), stratified by eczema assessed at 6 months, 1 year, 2 and 3 years of age; General linear models were employed for the analyses adjusted for gender, passive smoking and number of older children

	Eczema	6 months			p	Year 1			p	Year 2			P	Year 3			P
		GM	Lower	Upper		GM	Lower	Upper		GM	Lower	Upper		GM	Lower	Upper	
sIgA																	
6w	Yes	0.583	0.489	0.694	0.68	0.598	0.493	0.725	0.94	0.569	0.466	0.695	0.53	0.535	0.437	0.653	0.13
	No	0.607	0.510	0.722		0.593	0.505	0.697		0.608	0.520	0.713		0.631	0.540	0.739	
6m	Yes	0.567	0.463	0.692	0.97	0.629	0.505	0.784	0.17	0.552	0.436	0.699	0.79	0.530	0.414	0.679	0.50
	No	0.569	0.466	0.696		0.533	0.442	0.642		0.571	0.473	0.689		0.580	0.479	0.701	
Lysozyme																	
6w	Yes	0.067	0.054	0.082	0.77	0.068	0.054	0.085	0.67	0.064	0.050	0.082	0.89	0.069	0.054	0.088	0.35
	No	0.065	0.053	0.079		0.065	0.053	0.078		0.063	0.052	0.077		0.061	0.050	0.074	
6m	Yes	0.102	0.082	0.126	0.91	0.110	0.087	0.139	0.32	0.100	0.078	0.128	1.0	0.121	0.092	0.158	0.056
	No	0.100	0.081	0.124		0.097	0.079	0.118		0.100	0.081	0.123		0.092	0.075	0.112	
Lactoferrin																	
6w	Yes	2.795	2.300	3.395	0.008	2.517	2.020	3.135	0.53	2.672	2.116	3.378	0.18	2.866	2.240	3.670	0.054
	No	2.059	1.692	2.504		2.333	1.934	2.816		2.257	1.866	2.729		2.212	1.831	2.672	
6m	Yes	1.914	1.594	2.295	0.26	2.130	1.744	2.600	0.016	2.012	1.635	2.476	0.10	2.221	1.780	2.772	0.008
	No	1.699	1.416	2.038		1.640	1.390	1.936		1.677	1.414	1.987		1.619	1.371	1.911	
Total Protein																	
6w	yes	12.45	10.68	14.50	0.69	12.65	10.70	14.98	0.54	12.21	10.19	14.63	0.94	11.85	9.83	14.27	0.58
	No	12.03	10.34	13.98		11.99	10.41	13.80		12.29	10.65	14.19		12.53	10.82	14.49	
6m	yes	10.07	8.68	11.69	0.42	11.36	9.64	13.39	0.14	11.30	9.52	13.40	0.19	10.38	8.62	12.52	0.95
	No	10.80	9.33	12.51		9.95	8.69	11.40		10.02	8.73	11.50		10.45	9.10	12.01	

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

1 **Anti-infective proteins in breast milk and asthma-associated phenotypes during early childhood**

2

3

4 Zhang, Guicheng*¹; Lai, Ching Tat*²; Hartmann, Peter²; Oddy, Wendy H³; Kusel, Merci MH³; Sly,
5 Peter D⁴; Holt Patrick G^{3,4}

6 * contribute equally

7

8

9 ¹ School of Public Health, Curtin University, Perth, Western Australia, Australia

10 ² School of Chemistry and Biochemistry, Faculty of Science, The University of Western Australia,
11 Perth, Western Australia, Australia

12 ³ Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia

13 ⁴ University of Queensland, Queensland Children's Medical Research Institute, Brisbane, Queensland,
14 Australia

15

16

17 Running title: Breast milk proteins and risk for atopy/asthma

18

19

20 | Corresponding Author^s:

21

22 Prof Patrick G Holt

23 Professor P G Holt

24 Division of Cell Biology

25 Telethon Kids Institute

26 PO Box 855

27 West Perth WA 6872 Australia

28

29 Tel: +61 8 9489 7838

30 Email: Patrick.Holt@telethonkids.org.au

31 Marina.Stubbs@telethonkids.org.au

32

33 Dr Guicheng Zhang, School of Public Health, Curtin University

34 Email: brad.zhang@curtin.edu.au

35

36 | Word Count; [3022](#)

37

38 **Abstract**39 **Background**

40 The impact of breastmilk feeding on susceptibility to asthma in childhood is highly controversial, due
41 in part to failure of the majority of studies in the area to adequately account for key confounders
42 exemplified by respiratory infection history, plus the effects of recall bias.

44 **Methods**

45 As part of a prospective cohort study on the role of respiratory infections in asthma development in
46 high-risk children, we measured the concentration of a panel of anti-infective proteins in maternal milk
47 samples, and analysed associations between these and subsequent atopy-, infection- and asthma-related
48 outcomes prospectively to age 10 years.

50 **Results**

51 We observed significant but transient inverse associations between the concentration of milk proteins
52 and susceptibility to upper respiratory infections in year 1 only, and parallel but positive transient
53 associations with early lower respiratory infections and atopy. No associations were seen with asthma-
54 related outcomes.

56 **Conclusions**

57 Breast milk feeding may influence the expression of inflammatory symptoms associated with
58 respiratory infections and atopy in early life but these effects appear to be inconsistent and transient.
59 The heterogeneous nature of breastfeeding effects suggests it may influence systemic
60 immunoinflammatory function at several different levels.

61

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

62

63

64 Keywords: atopy, breast feeding, infancy, respiratory infection, wheezing, IgA, lysozyme, lactoferrin

65

66

67

For Peer Review

68 **Introduction**

69

70 Breastfeeding is widely acknowledged to have protective effects against a range of health problems in
71 infancy and childhood, as well as reducing risk for some chronic diseases that ~~persist into or~~ manifest
72 ~~de novo~~ in later life¹. Until comparatively recently, allergy-associated syndromes including atopic
73 asthma were paramount amongst the list of diseases reportedly susceptible to the protective effects of
74 breastfeeding,^{2,3} and recommendations for exclusive breastfeeding for the first 6 months of life have
75 been a prominent feature of many official guidelines aimed at allergy prevention^{4,5}.

76

77 However, a growing body of information derived from ~~retrospective and (in particular) prospective~~
78 birth cohort studies has questioned the validity of this paradigm. The relevant findings include
79 observations linking early introduction of allergenic foods with decreased risk of subsequent food
80 allergy^{6,7}, the lack of evidence from the large scale ISAAC study for any protective effect of exclusive
81 breastfeeding against eczema⁸, and suggestive evidence that in certain populations breastfeeding may
82 even *increase* long term risk for atopy and asthma^{9,10}.

83

84 The relationship between breastfeeding and asthma/allergic disease risk remains highly controversial.
85 Complicating this debate is the growing realization that the majority of the available studies which
86 have shaped current opinions in this area suffer from ~~significant~~ methodological flaws that mitigate
87 against reaching firm conclusions^{9,11}. The protective effects of breastfeeding on infection and allergic
88 conditions are known to be largely derived from the proteins of human milk¹². Amongst the most
89 important are secretory immunoglobulin A (sIgA), lysozyme and lactoferrin which are major whey
90 proteins ~~that make up approximately 40% of total protein in human milk which.~~ These proteins are
91 well known for their immune properties against a range of infections and diseases¹². Together with

4

92 other immune proteins in human milk, they assist infants to establish and strengthen their immunity
93 against infections and diseases later in life¹³.

94 Our aim in the present study was to ascertain whether these protein components of breast milk have
95 demonstrable activity in relation to protection of children against asthma and allergy. ~~We have~~
96 ~~established a longitudinal cohort that provides a novel opportunity to investigate this question.~~ The
97 findings reported below are derived from a subgroup of subjects from the Perth ~~Childhood Asthma~~
98 ~~Study (CAS)~~ cohort¹⁴⁻¹⁷, the design of which enables examination of this issue from a unique
99 perspective. Notably, this study had a primary focus on respiratory infection and as such included
100 physician verification and clinical assessment of all parent-reported putative infection events within the
101 first 5 years of life. Moreover, the subgroup from this cohort utilized for these analyses was restricted
102 to children whose mothers provided breast milk samples, and the study mothers were closely monitored
103 and supported by the clinical team including collection and analysis of breast milk samples at 6 weeks
104 and 6 months post partum. In addition to physician-monitoring of each respiratory infection event in
105 these children, objective assessment of allergy-associated and asthma-associated clinical phenotypes
106 was performed ~~by the same clinical team~~ at 6mths and annually to age 5 years, with ~~an~~-additional
107 followup at age 10 years. This approach enabled collection of a unique data set ~~that enables for~~
108 examination of the question of whether breast feeding influences allergy/asthma susceptibility from a
109 perspective not previously considered in detail i.e. whether differences in the concentration of key
110 protein constituents in milk (milk “quality”) were associated with ~~downstream~~-variations in ~~levels of~~
111 disease risk amongst recipients. The milk constituents chosen for these analyses were secretory
112 immunoglobulin A (sIgA), lysozyme and lactoferrin, in addition to total protein.

113

114 **Methodology**115 **Subjects**

116 ~~One hundred and forty two~~¹⁴² mother-~~and~~ infants pairs ~~participating in~~^{from} the ~~Childhood~~
117 ~~Asthma~~^{CAS Study cohort}^{16,17} (CAS) were included in the milk study. ~~Subjects in this study were part~~
118 ~~of an ongoing prospective birth cohort, as previously described~~^{16,17}. ~~Briefly,~~ the cohort was initiated
119 in 1996 ~~and continued from 1996 to 1998~~ in the Perth metropolitan area, all subjects were enrolled
120 antenatally and classified as having an atopic family history based on a standard questionnaire and a
121 positive doctor's diagnosis of asthma, hay fever, or atopic dermatitis for 1 or both parents. The cohort
122 has been follow up at 6 weeks, 6 months, 1, 2, 3, 4, 5 and 10 years with comprehensive assessment of
123 allergic and asthmatic ~~phenotype~~¹⁵⁻¹⁷ ~~phenotypes~~¹⁵⁻¹⁷.

124
125 Breastfeeding history was monitored through dietary questionnaire administered at the 6 weeks² and 6
126 months² visits and breast milk samples were collected at these visits. Infectious episodes were
127 prospectively recorded throughout the first 5 years ~~of each child's life~~ with a daily parental diary;
128 parents were trained to summon the clinical team at every incidence of suspected respiratory infection,
129 enabling symptom verification during the ensuing home visits by the clinical team. Acute respiratory
130 infections (ARIs) were subclassified as lower respiratory infection (LRI), wheezy lower respiratory
131 infection (wLRI) and upper respiratory infection (URI) ~~as detailed in the online supplement~~. ~~Any~~
132 ~~episode with runny/blocked nose or dry cough was classified as a URI. Episodes that were associated~~
133 ~~with wheeze, or cough and rattly chest were considered to be LRI. Rattle/rattly chest was described as~~
134 ~~moist, wet noisy breath sounds from the child's chest. Wheeze was defined as a high pitched whistling~~
135 ~~sound heard coming from the chest, on expiration. LRI were further classified into wLRI and non-~~
136 ~~wheezy LRI based on the presence of any wheeze reported by the parent or family doctor.~~ Skin prick
137 tests to a panel of ingested and aero- allergens were performed at 6 months, 2 years, 5 and 10 years to

138 define atopy. The subjects were examined for eczema on each of the scheduled followup visits as well
139 as during all home visits for respiratory episodes during the first 5 years. **Eczema was defined as**
140 **doctor diagnosis of eczema or atopic dermatitis experienced by child in last 12 months. Wheezing is**
141 **the parental opinion of whether child wheezed in last 12 months. Asthma was defined as wheeze during**
142 **last 12 months ([parent opinion](#)) plus Doctor diagnosis of asthma beyond the second birthday.**

143

144 ***Protein measurements***

145 The milk samples were stored at -20°C ~~prior to use for the study~~[after collection](#). Before ~~any~~
146 biochemical analysis, [thawed](#) milk samples were ~~thawed at room temperature, mixed and~~ centrifuged at
147 10000 RPM for 10 minutes. The tube was sliced to remove the fat layer. ~~The fat layer (the cloudy~~
148 ~~layer) was removed by slicing the tube at the bottom of the fat layer.~~The sIgA, lysozyme, lactoferrin
149 and total protein were assayed in the defatted milk.

150

151

152 ***Lysozyme analysis***

153 Lysozyme in the samples was ~~determined~~[measured](#) by a ~~simple assay that was modified~~
154 ~~from~~[modification of](#) Selsted & Martinez¹⁸. ~~The assay measured the loss of turbidity due to the lysis of~~
155 ~~Micrococcus lysodeikticus. The assay was modified that the reduction of the incubation time from 18~~
156 ~~hours to 6 hours was found to still provide an effective of standard range for the assay.~~

157

158 ***Lactoferrin and sIgA analysis***

159 Lactoferrin and sIgA in the samples was determined by ELISA ~~that was adapted from Tijssen~~¹⁹. ~~In the~~
160 ~~sIgA ELISA, three antibodies were used: primary antibody (Rabbit anti human IgA IgG, 6000 fold in~~
161 ~~PBS, DAKO), secondary antibody (Mouse anti human IgA IgG, 5000 fold in PBS/Tween containing~~

7

162 ~~1g/l BSA, DAKO) and third antibody (Goat anti mouse IgG IgG conjugated to horseradish~~
163 ~~peroxidase, 4000 fold in PBS/Tween containing 1g/l BSA, Bio Rad). Standard IgA from human~~
164 ~~colostrum was prepared in PBS/Tween (range from 0 to 0.4mg/ml, Sigma). Milk samples were diluted~~
165 ~~5000 fold in PBS/Tween for analysis.~~

166
167 ~~In the lactoferrin ELISA, two antibodies were used: primary antibody (anti human lactoferrin, 4000~~
168 ~~fold in PBS, ICN) and second antibody (anti human lactoferrin conjugated to HRP was diluted 5,000~~
169 ~~fold in PBS/Tween containing 1g/l BSA, ICN). Human lactoferrin standard was prepared in~~
170 ~~PBS/Tween (range from 0 to 0.02mg/ml, ICN). Milk samples were diluted 200,000 fold in PBS~~
171 ~~Tween.~~

172

173 **Total protein**

174 Total protein ~~in the samples~~ was determined by a protein assay that measured the binding of the protein
175 dye (Bio-Rad) to the primarily basic and aromatic amino acid residues of the proteins. [Further assay](#)
176 [details appear in the online supplement](#) ~~The dye was diluted 1:4 v/v and filtered with Whatman #1 filter~~
177 ~~paper prior to use. To overcome the problems inherent in the choice of a milk standard, the protein~~
178 ~~concentration of an aliquot of mature breast milk was determined by the Kjeldahl procedure^{20,21}. The~~
179 ~~remaining sample was then diluted with double deionised water to provide a range of standards (0 to~~
180 ~~1g/l). The defatted milk samples were diluted 30 fold for the assay. Standards and diluted samples~~
181 ~~(5µl) were pipetted into a microtitre plate (96 wells plate, ICN). The diluted dye reagent (250µl) was~~
182 ~~added and mixed with the plate mixer (WellMix2, Australia). The absorbance of each sample/standard~~
183 ~~was measure at 620nm with the Multiskan plate reader until the maximum absorbance was reached in~~
184 ~~approximately 20minutes.~~

185

Formatted: Plain Text

186 ***Statistical analysis***

187 ~~Levels of sIgA, lysozyme, lactoferrin and total p~~rotein ~~levels~~ were log-transformed to have an
188 approximately normal distribution. As the number of infectious episodes such as URI and LRI was a
189 count variable Poisson regression was employed to investigate the associations between levels of ~~sIgA,~~
190 ~~lysozyme, lactoferrin and total~~milk proteins and the incidence of respiratory infections ~~during first 3~~
191 ~~years of life~~. In order to examine the associations of breast milk proteins with binary outcomes such as
192 atopy ~~(defined by skin prick tests)~~, eczema, wheezing and asthma ~~at the different time points~~ we
193 compared the levels of these between the two scenarios of these binary outcomes using general linear
194 models after adjusting for gender, passive smoking and number of older siblings. All the analyses
195 were conducted using IBM SPSS Statistics 20.

196

197 **Results**

198 In this subcohort there were initially 142 infants. Five infants who were partly fed with formula were
199 subsequently excluded from the analyses. Table 1 shows the characteristics of 137 children included in
200 the present study and the remaining children in the longitudinal cohorts. The children for this study
201 appeared to have lower prevalence of smoking exposure and childcare attendance at age 1, compared
202 with the remaining children. Table 2 shows prevalence of these conditions in the 137 children who
203 completed the study.

204

205 ***Levels of breast milk proteins***

206 Within individual milk donors, the concentrations of sIgA, lactoferrin, lysozyme and total protein
207 varied between breasts at both six weeks and six months of lactation (Table 3). The range in the
208 concentrations of sIgA, lactoferrin, lysozyme and total protein from each breast at both six weeks and
209 six months of lactation was large (Table 3). At six weeks of lactation, the mean concentrations of the

9

210 right and left breasts for sIgA were (0.67 ± 0.36 g/l), lactoferrin was (2.59 ± 1.58), lysozyme was ($0.07 \pm$
211 0.07 g/l) and total protein was (15.1 ± 12.87 g/l) respectively. At six months of lactation, the mean
212 concentrations of the right and left breasts for sIgA were (0.71 ± 0.40 g/l), lactoferrin was (2.13 ± 1.29),
213 lysozyme was (0.11 ± 0.11 g/l) and total protein was (12.1 ± 5.84 g/l) respectively. There were
214 significant changes in the concentration of sIgA, lactoferrin, lysozyme and total protein in milk from
215 both breasts, except sIgA (left breast only), between six weeks and six months of lactation (data not
216 shown). All subsequent analyses utilized mean data from two breasts for each mother in the study.

217

218 *Atopy*

219 We investigated associations between the concentrations of breast milk proteins with atopy defined by
220 skin prick tests (SPT) at age 6 months, 2 and 5 years. We chose to measure atopy status at multiple
221 time points in light of our early demonstration¹⁴ that IgE production is commonly varied-cyclical over
222 time during the preschool years. The levels of milk proteins in the study population are shown in
223 Figure 1, stratified by atopy outcomes in their offspring at these three time points. sIgA concentrations
224 in milk samples collected at 6 months were significantly higher ($p = 0.019$) in the mothers whose
225 infants developed atopy by this age, compared with mothers of infants without atopy (Fig 1a). The 6
226 month lactoferrin levels were also significantly higher ($p = 0.022$) in this group (Fig 1c), as well as 6
227 week ($p = 0.028$) and 6 month ($p = 0.009$) total protein levels (Fig 1d). Similar effects were observed
228 with respect to total protein levels in maternal milk samples (Fig 1d), which were significantly higher
229 at both 6 weeks ($p = 0.001$) and 6 months ($p = 0.012$) in mothers whose infants developed atopy by age
230 2. It appeared that this relationship persisted up to outcome age 2 years but was lost by 5 years;
231 additional regression modeling of 10 year data also did not demonstrate significant associations
232 between milk protein content and atopy outcomes.

233

234 ***Eczema***

235 Eczema was assessed at ~~6 months, 1, 2, 3, 4, 5 and 10 years~~ each followup of in the longitudinal cohort.
236 We compared levels of individual breast milk proteins in offspring with and without eczema at these
237 time points after adjusting for gender, number of older children and passive smoking, and results out to
238 year 3 are shown in Table 4 (as above, unadjusted data yielded similar results). Positive associations
239 were observed between Lactoferrin levels and eczema outcomes at 6 months and 1 and 3 years, but not
240 beyond these time points (not shown) with an exception that a marginal effect of milk lysozyme at 6
241 months on current eczema at age 10 was also observed. (p=0.048).

242

243 ***Respiratory infections***

244 We assessed ~~the~~ associations between levels of ~~maternal~~ ~~maternal~~-milk proteins and ~~the~~ risk in their
245 offspring for respiratory infections in the first 3 years ~~of life~~, using Poisson regression models and
246 adjusting for gender, passive smoking and number of older ~~children~~ ~~siblings~~. Generally, the presence of
247 high levels of anti-infective proteins were associated with reduced frequency of URIs (IRR<1) in the
248 first two years of life (Supplementary Table 1). sIgA levels were associated with a decreased risk for
249 URIs in the first year of life at a significance of p = 0.035 and 0.079 for milk samples collected at 6
250 weeks and 6 months, respectively, and similarly for Lactoferrin levels in 6 month samples (p=0.008).
251 With respect to year 2 URI outcomes, 6 week IgA and 6 month Lactoferrin levels were also
252 significantly associated with a decreased risk for URI (~~p=~~ ~~values of~~ 0.005 and 0.015 respectively).
253 These associations diminished beyond year 2.

254

255 No associations were observed that were consistent with parallel milk-mediated protection against the
256 spread and/or intensification of infections in the lower respiratory tract. Instead, high levels of
257 Lactoferrin and/or Lysozyme in early milk samples were paradoxically associated with increased risk

258 for wheezing lower respiratory infections, but only during the first year of life ([Supplementary Table](#)
259 [2](#)).

260

261 *Wheezing and asthma*

262 Current wheezing was evaluated at [ages 1, 2, 3, 4, 5 and 10 years each annual visit](#) and asthma was
263 defined at ages 3, 4, 5 and 10 years. No significant associations were found between the concentrations
264 of breast milk proteins with these phenotypes employing either adjusted or raw data utilized above (not
265 shown). In followup analyses we also tested multiple regression models in which qualitative and
266 quantitative respiratory tract infection history over the first two years of life were included as additional
267 confounders, and again could not identify any significant linkages between milk protein levels and
268 asthma-associated phenotypes (data not shown).

269

270 **Discussion**

271 The focus of studies in the [Perth Childhood Asthma Study \(CAS\)](#) birth cohort is on identification of
272 factors driving [asthma](#) pathogenesis ~~of asthma~~ during childhood. Our previous investigations in this
273 cohort have identified early allergic sensitization and [early-concomitant](#) respiratory tract infections,
274 ~~particularly during the first two years of life,~~ as major asthma risk factors¹⁶. These can operate
275 independently to drive asthma development, however the highest level of risk is observed in children
276 who experience both sensitization ~~to perennial aeroallergens~~ and respiratory tract infections
277 concomitantly during this period¹⁴. The initial diagnosis of asthma in the cohort was made at age 5
278 years¹⁶, but more recently it was shown that these effects carry through to at least 10 years¹⁵. It is
279 additionally noteworthy that the relevant infections are those that spread to the lower respiratory tract
280 and attain sufficient severity to trigger symptoms of wheeze and/or fever, whereas infections that
281 remain restricted to the upper respiratory tract are benign in this context ^{15,16}.

282

283 It is reasonable to consider breast milk intake as a potential factor that may modulate asthma risk in
284 CAS cohort subjects for a number of reasons, in particular (i) an earlier literature suggesting that breast
285 milk feeding can protect against allergic sensitization (e.g.³); (ii) the well established role of
286 breastfeeding in protecting infants against both enteric and respiratory infections²²; and (iii) the reports
287 from earlier observational studies linking exclusive breast feeding with reduced rates of subsequent
288 wheeze²³⁻²⁵.

289

290 These claims have biological plausibility at several levels. Notably, it has been established that innate
291 and adaptive immune functions in all infants are in a functionally quiescent state at birth²⁶⁻²⁸, and
292 mature postnatally in response to environmental microbial stimulation, especially from commensal
293 organisms in the gastrointestinal tract (reviewed^{29,30}) but also from common childhood infections (the
294 “Hygiene Hypothesis”³¹). However, as noted above, certain categories of severe respiratory infections
295 appear to have the opposite effects in relation to risk of asthma, likely due in part to direct
296 inflammatory damage to developing lung function extrinsic to any influence on immune system
297 maturation³².

298

299 The kinetics of postnatal immune maturation is ~~constitutively~~ sluggish in a significant subset of
300 children at high risk of developing atopy/asthma^{33,34}, and hence factors that modulate exposure to
301 common and relatively benign childhood infections, and/or patterns of colonization with commensal
302 microflora, may influence this process in ways that cannot be predicted. In this regard it is noteworthy
303 that a growing literature has implicated breast milk feeding as an important modulator of quantitative
304 and qualitative aspects of postnatal bacterial colonization of the GIT³⁵⁻³⁷.

305

306 | These complexities may explain some of the disparities in the ~~published~~ literature on relationships
307 | between breast feeding and future atopy/asthma outcomes, and likewise some of the apparent
308 | contradictions in our findings above from the CAS cohort. Notably, a clear finding in these subjects
309 | was the inverse association between levels of the anti-infectives IgA and Lactoferrin in milk and risk
310 | for upper respiratory infections in year 1, which extended into year 2 (Table 4). However, these
311 | protective effects were not seen with respect to the lower respiratory tract, and instead levels of milk
312 | proteins (in this case Lactoferrin and Lysozyme) were positively associated with risk for wheezing
313 | infections (Table 5). Similar positive relationships were observed between levels of milk proteins and
314 | early atopic outcomes measured as either SPT reactivity (Figs 1 and 2) or eczema Table 3; Fig 3); in
315 | both cases these effects were transient and were not generally seen beyond ~~age~~-2 years. In this regard
316 | we have previously reported that increased amounts of omega-3 fatty acids in maternal milk at 6 weeks
317 | protected against eczema at 6 months, but this protection did not continue to later ages³⁸.

318

319 | The dichotomous nature of our findings cannot be fully explained, but some possibilities can be
320 | considered. Firstly, breast milk feeding-associated protection against relatively mild URI at/around the
321 | time of infancy is not unexpected and is consistent with what is known re the anti-infective properties
322 | of maternal milk mediated via direct effects of anti-microbial molecules on incoming pathogens.

323

324 | However the reasons for dissociation between these URI effects and those relating to susceptibility to
325 | atopy and/or the spread of infections to the LRI are unclear. Possible explanations include (i) these
326 | severe LRI events may reflect higher pathogen loads that are beyond the range that is potentially
327 | controllable by milk-born anti-infectives; (ii) resistance to infection spread/intensification and to atopic
328 | sensitization in infants may depend upon defence mechanisms that are discrete from those that protect
329 | against URI, in particular cellular immune mechanisms that are reliant upon “endogenous” maturation-

330 inducing microbial signals, particularly from GIT commensals, colonization with which is likely
331 influenced by milk-born anti-infectives. However it is not feasible to directly test these possibilities
332 with the available data.

333

334 The most clearcut finding in our study is the lack of ~~any~~ discernible milk protein quality-associated
335 effects on asthma-related outcomes that persist beyond early childhood. It is pertinent to reiterate that
336 these outcomes have been shown to be highly sensitive to early history of both atopy and LRI in this
337 cohort¹⁴⁻¹⁶, which as noted above are transiently influenced by breast milk quality, but apparently not to
338 a degree which influences subsequent susceptibility to asthma. Our findings are thus consistent with the
339 growing body of evidence suggesting that the long-term benefits of breast milk feeding in relation to
340 these atopy- and asthma-associated phenotypes are limited⁶⁻¹⁰ but we cannot completely exclude effects
341 based on our study because our sample size is small. We have described all statistical analyses carried
342 out and did not make multiple test corrections because (i) they can be overly conservative and may
343 inflate type II errors and (ii) our analyses were based on an *a priori* hypothesis³⁹.

344

345 In conclusion it is relevant to acknowledge the limitations of this study. Firstly regarding the lack of
346 association between wheezing/asthma and levels of milk proteins we acknowledge the possible type II
347 errors due to relatively small sample size, which also precluded further sub-group analysis on the
348 effects of milk proteins on other outcomes. However, this is a longitudinal cohort with wheezing
349 phenotypes comprehensively investigated, which is superior to a cross-sectional study. There were
350 strong correlations between levels of individual proteins and the total milk proteins. We, therefore,
351 could not further clarify the effects of individual proteins in this cohort. Additionally, ~~While while~~
352 unlike previous investigations we have been able to include comprehensive data relating to the
353 potential confounding effects of infection history in regression models of milk-related effects on

354 asthma-associated outcomes, this remains a relatively small study, and larger sample sizes with greater
355 statistical power may be required to finally resolve this issue. ~~Additionally Also~~, our study population
356 are all at high genetic risk for atopy/asthma and thus representative of 40-45% of the pediatric
357 population, and accordingly are not representative of the general population.

358

Formatted: Font: Font color: Red, (Asian)
Chinese (PRC), (Other) English (Australia)

For Peer Review

359 **Figure legends:**

360 Figure 1 The adjusted geometric means (g/l) and 95% confidence intervals of milk proteins collected at
361 6 weeks (6w) and 6 months (6m), stratified by atopy assessed using skin prick tests at 6 months, 2 and
362 5 years of age; General linear models were employed for the analyses with gender, passive smoking
363 and number of older children adjusted for; a: sIgA, b: Lysozyme, c: Lactoferrin, and d: Total Protein;

364 ■ : Solid square, children with atopy (yes) △ : Open triangle, children without atopy (no)

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379


380

381

382

383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406

For Peer Review



407 **References**

408

- 409 1. Dieterich CM, Felice JP, O'Sullivan E, Rasmussen KM. Breastfeeding and health outcomes for
410 the mother-infant dyad. *Pediatr Clin North Am* 2013;60:31-48.
- 411 2. Oddy WH, de Klerk NH, Sly PD, Holt PG. The effects of respiratory infections, atopy, and
412 breastfeeding on childhood asthma. *European Respiratory Journal* 2002;19:899-905.
- 413 3. Oddy WH, Holt PG, Sly PD, et al. Association between breast feeding and asthma in 6 year old
414 children: findings of a prospective birth cohort study. *BMJ (Clinical research ed)* 1999;319:815-9.
- 415 4. NHMRC. Eat for Health: Australian Dietary Guidelines. In: Australia NHMRC, ed.: National
416 Health and Medical Research Council of Australia; 2013:36.
- 417 5. Kramer MS, Kakuma R. The optimal duration of exclusive breastfeeding: a systematic review.
418 *Adv Exp Med Biol* 2004;554:63-77.
- 419 6. Du Toit G, Katz Y, Sasieni P, et al. Early consumption of peanuts in infancy is associated with
420 a low prevalence of peanut allergy. *J Allergy Clin Immunol* 2008;122:984-91.
- 421 7. Koplin JJ, Osborne NJ, Wake M, et al. Can early introduction of egg prevent egg allergy in
422 infants? A population-based study. *J Allergy Clin Immunol* 2010;126:807-13.
- 423 8. Flohr C, Nagel G, Weinmayr G, et al. Lack of evidence for a protective effect of prolonged
424 breastfeeding on childhood eczema: lessons from the International Study of Asthma and Allergies in
425 Childhood (ISAAC) Phase Two. *Br J Dermatol* 2011;165:1280-9.
- 426 9. Sears MR, Greene JM, Willan AR, et al. Long-term relation between breastfeeding and
427 development of atopy and asthma in children and young adults: a longitudinal study. *Lancet*
428 2002;360:901-7.
- 429 10. Wright AL, Holberg CJ, Taussig LM, Martinez FD. Factors influencing the relation of infant
430 feeding to asthma and recurrent wheeze in childhood. *Thorax* 2001;56:192-7.

- 431 11. Matheson MC, Allen KJ, Tang ML. Understanding the evidence for and against the role of
432 breastfeeding in allergy prevention. *Clin Exp Allergy* 2012;42:827-51.
- 433 12. Lonnerdal B. Bioactive proteins in human milk: mechanisms of action. *The Journal of*
434 *pediatrics* 2010;156:S26-30.
- 435 13. Walker A. Breast milk as the gold standard for protective nutrients. *The Journal of pediatrics*
436 2010;156:S3-7.
- 437 14. Holt P, Rowe J, Kusel M, et al. Towards improved prediction of risk for atopy and asthma
438 amongst preschoolers: a prospective cohort study. *J Allergy Clin Immunol* 2010;125:645-51.
- 439 15. Kusel M, Kebabze T, Johnston S, Holt P, Sly P. Febrile respiratory illnesses in infancy and
440 atopy are risk factors for persistent asthma and wheeze. *European Respiratory Journal* 2012;39:876-82.
- 441 16. Kusel MM, de Klerk NH, Kebabze T, et al. Early-life respiratory viral infections, atopic
442 sensitization, and risk of subsequent development of persistent asthma. *Journal of Allergy and Clinical*
443 *Immunology* 2007;119:1105-10.
- 444 17. Kusel MMH, de Klerk NH, Holt PG, Kebabze T, Johnston SL, Sly PD. Role of respiratory
445 viruses in acute upper and lower respiratory tract illness in the first year of life - A birth cohort study.
446 *Pediatric Infectious Disease Journal* 2006;25:680-6.
- 447 18. Selsted ME, Martinez RJ. A simple and ultrasensitive enzymatic assay for the quantitative
448 determination of lysozyme in the picogram range. *Anal Biochem* 1980;109:67-70.
- 449 19. Tijssen P. Laboratory techniques in biochemistry and molecular biology. In: Burdon RHavK,
450 P.H., ed. *Practice and theory of immunoessays*. New York: Elsevier; 1985.
- 451 20. Atwood CS, Hartmann PE. Collection of fore and hind milk from the sow and the changes in
452 milk composition during suckling. *J Dairy Res* 1992;59:287-98.
- 453 21. Hambraeus L, Lonnerdal B, Forsum E, Gebre-Medhin M. Nitrogen and protein components of
454 human milk. *Acta Paediatr Scand* 1978;67:561-5.

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

- 455 22. Paramasivam K, Michie C, Opara E, Jewell AP. Human breast milk immunology: a review. *Int*
456 *J Fertil Womens Med* 2006;51:208-17.
- 457 23. Aberg N, Engstrom I, Lindberg U. Allergic diseases in Swedish school children. *Acta Paediatr*
458 *Scand* 1989;78:246-52.
- 459 24. Chandra RK. Five-year follow-up of high-risk infants with family history of allergy who were
460 exclusively breast-fed or fed partial whey hydrolysate, soy, and conventional cow's milk formulas. *J*
461 *Pediatr Gastroenterol Nutr* 1997;24:380-8.
- 462 25. Kaufman HS, Frick OL. The development of allergy in infants of allergic parents: a prospective
463 study concerning the role of heredity. *Ann Allergy* 1976;37:410-5.
- 464 26. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. *Nat Rev*
465 *Immunol* 2007;7:379-90.
- 466 27. Siegrist CA. Vaccination in the neonatal period and early infancy. *Int Rev Immunol*
467 2000;19:195-219.
- 468 28. Holt PG. Postnatal maturation of immune competence during infancy and childhood [Review].
469 *Pediatric Allergy and Immunology* 1995;6:59-70.
- 470 29. Holt PG. Environmental factors and primary T-cell sensitization to inhalant allergens in
471 infancy: reappraisal of the role of infections and air pollution [Review]. *Pediatric Allergy and*
472 *Immunology* 1995;6:1-10.
- 473 30. Rook GA, Stanford JL. Give us this day our daily germs. *Immunology Today* 1998;19:113-6.
- 474 31. Strachan DP. Hay fever, hygiene, and household size. *Br Med J* 1989;299:1259-60.
- 475 32. Holt PG, Sly PD. Viral Infections and atopy in asthma pathogenesis: new rationales for asthma
476 prevention and treatment. *Nature Medicine* 2012;18:726-35.
- 477 33. Holt PG, Clough JB, Holt BJ, et al. Genetic 'risk' for atopy is associated with delayed postnatal
478 maturation of T-cell competence. *Clinical and Experimental Allergy* 1992;22:1093-9.

- 479 34. Prescott SL, Macaubas C, Smallacombe T, Holt BJ, Sly PD, Holt PG. Development of allergen-
480 specific T-cell memory in atopic and normal children. *Lancet* 1999;353:196-200.
- 481 35. Favier CF, de Vos WM, Akkermans AD. Development of bacterial and bifidobacterial
482 communities in feces of newborn babies. *Anaerobe* 2003;9:219-29.
- 483 36. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in
484 patients with recurrent malignant glioma. *J Clin Oncol* 2000;18:646-50.
- 485 37. Kleessen B, Bunke H, Tovar K, Noack J, Sawatzki G. Influence of two infant formulas and
486 human milk on the development of the faecal flora in newborn infants. *Acta Paediatr Scand*
487 1995;84:1347-56.
- 488 38. Oddy WH, Pal S, Kusel MM, et al. Atopy, eczema and breast milk fatty acids in a high-risk
489 cohort of children followed from birth to 5 yr. *Pediatr Allergy Immunol* 2006;17:4-10.
- 490 39. Perneger TV. What's wrong with Bonferroni adjustments. *BMJ (Clinical research ed)*
491 1998;316:1236-8.

492

493

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

Table 1 The comparison of the 137 children and the remaining children in the longitudinal cohort

	137 children for milk protein analysis n/N (%)	Remaining children n/N (%)	p
Males	83/137 (60.6)	63/124 (50.8)	0.11
Maternal atopy history	106/135 (78.5)	71/89 (79.8)	0.82
Paternal atopy history	92/135 (68.1)	59/89 (66.3)	0.77
Exposure to passive smoking at age 1	19/134 (14.2)	25/93 (26.9)	0.017
Exposure to passive smoking at age 5	13/122 (10.7)	17/76 (22.4)	0.025
Childcare attendance at age 1	32/134 (23.9)	34/93 (36.6)	0.039
Childcare attendance at age 5	52/129 (40.3)	45/91 (49.5)	0.18
Asthma at age 5	23/122 (18.9)	12/76 (15.8)	0.58

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

Table 2 Allergic phenotypes in the 137 children included in the study

	6 months		1 year		2 year		3 years		4 years		5 years		10 years	
	n/N	%	n/N	%	n/N	%	n/N	%	n/N	%	n/N	%	n/N	%
Atopy	28/131	21.4	-	-	58/131	44.3	-	-	-	-	47/119	39.5	69/84	82.1
Eczema	68/137	49.6	52/137	38.0	48/131	36.6	37/127	29.1	37/125	29.6	35/122	28.7	25/97	25.8
Wheezing	-	-	46/137	33.6	40/131	30.5	38/127	29.9	33/125	26.4	36/122	29.5	11/96	11.5
Asthma	-	-	-	-	-	-	-	-	-	-	23/122	18.9	14/95	14.7

n: number children with the condition, N: total number of children; Atopy: Skin prick test positive to one or more allergens (wheal size >2 mm); Eczema: Doctor diagnosis of eczema or atopic dermatitis experienced by child in last 12 months; Wheezing: parental opinion of whether child wheezed in last 12 months; Asthma: wheeze during last 12 months plus Doctor diagnosis of asthma beyond the second birthday

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

Table 3 Concentrations (g/l) of milk proteins

		At 6 weeks			At 6 months			
		n	Mean	SD	n	Mean	SD	p
sIgA	Right	135	0.709	0.443	134	0.712	0.479	0.67
	Left	136	0.620	0.390	133	0.710	0.475	
	Average	134	0.669	0.358	132	0.711	0.400	
Lysozyme	Right	136	0.077	0.088	133	0.099	0.102	<0.001
	Left	135	0.071	0.078	131	0.127	0.154	
	Average	134	0.074	0.071	131	0.113	0.110	
Lactoferrin	Right	134	2.670	1.861	132	2.326	1.874	<0.001
	Left	135	2.526	1.896	130	1.900	1.363	
	Average	133	2.598	1.579	130	2.126	1.289	
Total protein	Right	136	14.867	8.655	132	12.696	7.107	<0.001
	Left	135	15.497	21.248	129	11.310	6.229	
	Average	134	15.145	12.873	129	12.056	5.842	

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

Table 4 Adjusted geometric means (g/l) and 95% confidence intervals of milk proteins collected at 6 weeks (6w) and 6 months (6m), stratified by eczema assessed at 6 months, 1 year, 2 and 3 years of age; General linear models were employed for the analyses adjusted for gender, passive smoking and number of older children

	Eczema	6 months				Year 1				Year 2				Year 3			
		GM	Lower	Upper	p	GM	Lower	Upper	p	GM	Lower	Upper	P	GM	Lower	Upper	P
sIgA																	
6w	Yes	0.583	0.489	0.694	0.68	0.598	0.493	0.725	0.94	0.569	0.466	0.695	0.53	0.535	0.437	0.653	0.13
	No	0.607	0.510	0.722		0.593	0.505	0.697		0.608	0.520	0.713		0.631	0.540	0.739	
6m	Yes	0.567	0.463	0.692	0.97	0.629	0.505	0.784	0.17	0.552	0.436	0.699	0.79	0.530	0.414	0.679	0.50
	No	0.569	0.466	0.696		0.533	0.442	0.642		0.571	0.473	0.689		0.580	0.479	0.701	
Lysozyme																	
6w	Yes	0.067	0.054	0.082	0.77	0.068	0.054	0.085	0.67	0.064	0.050	0.082	0.89	0.069	0.054	0.088	0.35
	No	0.065	0.053	0.079		0.065	0.053	0.078		0.063	0.052	0.077		0.061	0.050	0.074	
6m	Yes	0.102	0.082	0.126	0.91	0.110	0.087	0.139	0.32	0.100	0.078	0.128	1.0	0.121	0.092	0.158	0.056
	No	0.100	0.081	0.124		0.097	0.079	0.118		0.100	0.081	0.123		0.092	0.075	0.112	
Lactoferrin																	
6w	Yes	2.795	2.300	3.395	0.008	2.517	2.020	3.135	0.53	2.672	2.116	3.378	0.18	2.866	2.240	3.670	0.054
	No	2.059	1.692	2.504		2.333	1.934	2.816		2.257	1.866	2.729		2.212	1.831	2.672	
6m	Yes	1.914	1.594	2.295	0.26	2.130	1.744	2.600	0.016	2.012	1.635	2.476	0.10	2.221	1.780	2.772	0.008
	No	1.699	1.416	2.038		1.640	1.390	1.936		1.677	1.414	1.987		1.619	1.371	1.911	
Total Protein																	
6w	yes	12.45	10.68	14.50	0.69	12.65	10.70	14.98	0.54	12.21	10.19	14.63	0.94	11.85	9.83	14.27	0.58
	No	12.03	10.34	13.98		11.99	10.41	13.80		12.29	10.65	14.19		12.53	10.82	14.49	
6m	yes	10.07	8.68	11.69	0.42	11.36	9.64	13.39	0.14	11.30	9.52	13.40	0.19	10.38	8.62	12.52	0.95
	No	10.80	9.33	12.51		9.95	8.69	11.40		10.02	8.73	11.50		10.45	9.10	12.01	

Dear Dr Paolo Matricardi:

Re: PAI14-O-0162.R1

Thank you very much for further reviewing our manuscript. We are grateful for the constructive comments and suggestions of the reviewers, and have revised the paper accordingly. Attached please find the revised manuscript. Our responses to the comments raised and corresponding changes made are listed below. We believe that all the issues raised have been addressed satisfactorily, and trust that the paper is now acceptable for publication in PAI. Thank you once again for your kind consideration.

Yours sincerely,

Professor P G Holt
Division of Cell Biology
Telethon Kids Institute
PO Box 855
West Perth WA 6872 Australia

Editor's comments:

In Addition, the Editorial Office ask you to reduce the number of tables from 6 to 4 by shifting the tables 5 and 6 (or others at your choice) in the electronic repository. The text is also exceeding the limit, please consider to shift paragraphs (at your choice) in the electronic repository.

Response: Tables 5 and 6 have been shifted in the electronic repository. To reduce the text we have shifted several paragraphs in the electronic repository and deleted redundant words. Word Count; 3022

Reviewer: 1

1. Overall fine, most points were addressed adequately. However, some points are still not clear and should be implemented to make the message and potential limitations as transparent as possible for the reader.

Response: We have added sentences in the discussion section to clarify the limitations of the study (Lines 298-304/Pages 13, 14 in the clean version).

2. Comment 18. Further, no logic is provided for thinking that the relations with atopy, for example, might be different at 6 months vs. 2 or 5 years.

Revised (Lines 215-217).

Line 215-217: there is a word missing.

Response: The missing word "cyclical" was added. The rationale is already present in the text (line 176/page 8).

Reviewer: 2

1. Definition of asthma (and other) outcomes: was this current asthma, during the last 12 months, asthma ever (similar for other outcomes): please specify. Were lung function data at later ages included in confirmation of the diagnosis? What about coexistence of diagnoses?

Response: In the cohort lung function was only measured in 10 years follow up and we have provided the definition of the outcome variables such as wheezing, asthma, atopy and eczema.

The definition of asthma and other outcomes is now included in the Legend of Table 2, correct? However, it would make it helpful for the reader to specifically explain it in a) either methods or b) results. Here, it needs to be included that wheeze was defined by parental opinion (which is well known to be subjective and often not corresponding well with a doctor diagnosis) AND doctor diagnosis of asthma beyond the second birthday.

And what about coexistence of diagnoses? This was not elucidated further.

Response: We have added the following sentences (in red) in the methodology section (Lines 129-132/Page 6):

"Eczema was defined as doctor diagnosis of eczema or atopic dermatitis experienced by child in last 12 months. Wheezing is the parental opinion of whether child wheezed in last 12 months. Asthma was defined as wheeze during last 12 months plus Doctor diagnosis of asthma beyond the second birthday."

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

There was coexistence of diagnoses such as eczema and wheezing. Due to sample size we did not investigate the associations of coexistence of allergic symptoms with anti-infective proteins in breast milk.

4. Did you also perform longitudinal analyses on other outcomes than atopy and eczema? Please provide data on wheezing and/or asthma. Was an analysis performed on children which presented with consistent diagnoses over all ages? This may actually be the strongest outcome as compared to effects on different time frames, certainly giving additive information. How do the authors explain changes in prevalence at the different ages? This is particularly different for atopy. This also relates to the specific definition of the diagnoses (see point 1).

Response: Data from the published cohort studies indicate that the expression of both wheezing and atopic phenotypes fluctuates over time in children during the preschool years. We have provided the results for wheezing and asthma (Lines 255-262). We did not find significant associations between wheezing/asthma and milk protein levels in the cohort. For the relatively small sample size of the sub-group of the cohort we do not have power to further investigate the effects of milk proteins on transient/early or persistent/late onset wheezing. We also acknowledge that multiple tests may give some false positive associations.

This part should be discussed and included as limitation in the discussion.

Response: We have added following sentences in the discussion section (Lines 198-302/Pages 13,14):

“Firstly regarding the lack of association between wheezing/asthma and levels of milk proteins we acknowledge the possible type II errors due to relatively small sample size, which also precluded further sub-group analysis on the effects of milk proteins on other outcomes. However, this is a longitudinal cohort with wheezing phenotypes comprehensively investigated, which is superior to a cross-sectional study.”

6. The clearest and consistent findings seem to be the change in protein concentration. For the other graphs (e.g. Fig. 1) findings do not seem to be that consistent. Did you try adjusting your data for total protein concentration?





Response: Due to the high correlation and colinearity between individual protein and total protein concentration adjusting for total protein concentration is questionable. With the dataset we cannot further clarify the effects of individual proteins.

Also, this last part should be included as limitation in the discussion to be transparent.

Response: We have added the following sentence in the discussion section (Lines 302-304/Page 14):

“There were strong correlations between levels of individual proteins and the total milk proteins. We, therefore, could not further clarify the effects of individual proteins in this cohort.”

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. Pediatric Allergy and Immunology. 25 (6): pp. 544-551.



Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

Anti-infective proteins in breast milk and asthma-associated phenotypes during early childhood

Zhang, Guicheng^{*1}; Lai, Ching Tat^{*2}; Hartmann, Peter²; Oddy, Wendy H³; Kusel, Merci MH³; Sly, Peter D⁴; Holt Patrick G^{3,4}

* contribute equally

¹ School of Public Health, Curtin University, Perth, Western Australia, Australia

² School of Chemistry and Biochemistry, Faculty of Science, The University of Western Australia, Perth, Western Australia, Australia

³ Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia

⁴ University of Queensland, Queensland Children's Medical Research Institute, Brisbane, Queensland, Australia

Running title: Breast milk proteins and risk for atopy/asthma

Corresponding Author

Prof Patrick G Holt
Professor P G Holt
Division of Cell Biology
Telethon Kids Institute
PO Box 855
West Perth WA 6872 Australia

Tel: +61 8 9489 7838
Email: Patrick.Holt@telethonkids.org.au
Marina.Stubbs@telethonkids.org.au

Dr Guicheng Zhang, School of Public Health, Curtin University
Email: brad.zhang@curtin.edu.au

Classification of LRI episodes

Any episode with runny/blocked nose or dry cough was classified as a URI. Episodes that were associated with wheeze, or cough and rattly chest were considered to be LRI. Rattle/rattly chest was described as moist, wet noisy breath sounds from the child's chest. Wheeze was defined as a high-pitched whistling sound heard coming from the chest, on expiration. LRI were further classified into wLRI and non-wheezy LRI based on the presence of any wheeze reported by the parent or family doctor.

Lysozyme analysis

Lysozyme in the samples was determined by a simple assay that was modified from Selsted & Martinez¹⁸. The assay measured the loss of turbidity due to the lysis of *Micrococcus lysodeikticus*. The assay was modified that the reduction of the incubation time from 18 hours to 6 hours was found to still provide an effective of standard range for the assay.

Lactoferrin and sIgA analysis

Lactoferrin and sIgA in the samples was determined by ELISA that was adapted from Tijssen¹⁹. In the sIgA ELISA, three antibodies were used: primary antibody (Rabbit anti-human - IgA IgG, 6000 fold in PBS, DAKO), secondary antibody (Mouse anti- human - IgA IgG, 5000 fold in PBS/Tween containing 1g/l BSA, DAKO) and third antibody (Goat anti- mouse - IgG IgG conjugated to horseradish peroxidase, 4000 fold in PBS/Tween containing 1g/l BSA, Bio-Rad). Standard IgA from human colostrum was prepared in PBS/Tween (range from 0 to 0.4mg/ml, Sigma). Milk samples were diluted 5000 fold in PBS/Tween for analysis.

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

In the lactoferrin ELISA, two antibodies were used: primary antibody (anti- human lactoferrin, 4000 fold in PBS, ICN) and second antibody (anti- human lactoferrin conjugated to HRP was diluted 5,000 fold in PBS/Tween containing 1g/l BSA, ICN). Human lactoferrin standard was prepared in PBS/Tween (range from 0 to 0.02mg/ml, ICN). Milk samples were diluted 200,000 fold in PBS Tween.

Total protein

Total protein in the samples was determined by a protein assay that measured the binding of the protein dye (Bio-Rad) to the primarily basic and aromatic amino acid residues of the proteins. The dye was diluted 1:4 v/v and filtered with Whatman #1 filter paper prior to use. To overcome the problems inherent in the choice of a milk standard, the protein concentration of an aliquot of mature breast milk was determined by the Kjeldahl procedure^{20,21}. The remaining sample was then diluted with double deionised water to provide a range of standards (0 to 1g/l). The defatted milk samples were diluted 30-fold for the assay. Standards and diluted samples (5µl) were pipetted into a microtitre plate (96 wells plate, ICN). The diluted dye reagent (250µl) was added and mixed with the plate mixer (WellMix2, Australia). The absorbance of each sample/standard was measure at 620nm with the Multiskan plate reader until the maximum absorbance was reached in approximately 20minutes.

Supplementary Table 1 Incidence rate ratios (IRR) of breast milk proteins for upper respiratory infection in the first three years of life; Poisson regression models were employed for the analyses adjusted for gender, passive smoking and number of older children

		IRR	p	95% CI	
				Lower	Upper
Year 1					
Log value of sIgA	6W	0.830	0.035	0.698	0.987
	6M	0.881	0.079	0.765	1.015
Log value of Lysozyme	6W	0.993	0.93	0.861	1.147
	6M	0.952	0.482	0.829	1.093
Log value of Lactoferrin	6W	0.957	0.544	0.832	1.102
	6M	0.803	0.008	0.682	0.945
Log value of total proteins	6W	0.928	0.457	0.761	1.131
	6M	0.867	0.172	0.707	1.064
Year 2					
Log value of sIgA	6W	0.793	0.005	0.673	0.934
	6M	0.934	0.409	0.795	1.098
Log value of Lysozyme	6W	0.960	0.574	0.831	1.108
	6M	1.073	0.316	0.935	1.231
Log value of Lactoferrin	6W	0.886	0.083	0.772	1.016
	6M	0.814	0.015	0.691	0.960
Log value of total proteins	6W	0.860	0.139	0.705	1.050
	6M	0.892	0.267	0.730	1.091
Year 3					
Log value of sIgA	6W	1.074	0.455	0.891	1.294
	6M	1.125	0.150	0.958	1.321
Log value of Lysozyme	6W	0.973	0.710	0.841	1.125
	6M	1.013	0.860	0.881	1.164
Log value of Lactoferrin	6W	0.991	0.909	0.851	1.155
	6M	0.955	0.599	0.805	1.134
Log value of total proteins	6W	0.987	0.905	0.793	1.228
	6M	0.869	0.211	0.698	1.082

Zhang, G. and Lai, C. and Hartmann, P. and Oddy, W. and Kusel, M. and Sly, P. and Holt, P. 2014. Anti-Infective Proteins in Breast Milk and Asthma-Associated Phenotypes During Early Childhood. *Pediatric Allergy and Immunology*. 25 (6): pp. 544-551.

Supplementary Table 2 Incidence rate ratios (IRR) of breast milk proteins for wheezing lower respiratory infection in the first three years of life; Poisson regression models were employed for the analyses with gender, passive smoking and number of older children adjusted for

		IRR	p	95% CI	
				Lower	Upper
Year 1					
Log value of sIgA	6W	0.777	0.283	0.491	1.231
	6M	1.364	0.170	0.876	2.126
Log value of Lysozyme	6W	1.437	0.047	1.004	2.055
	6M	1.783	0.001	1.277	2.488
Log value of Lactoferrin	6W	1.893	0.003	1.245	2.880
	6M	1.455	0.103	0.927	2.284
Log value of total proteins	6W	1.088	0.745	0.655	1.805
	6M	1.580	0.123	0.883	2.825
Year 2					
Log value of sIgA	6W	0.978	0.904	0.674	1.417
	6M	0.974	0.894	0.662	1.433
Log value of Lysozyme	6W	1.160	0.354	0.847	1.589
	6M	1.236	0.181	0.906	1.687
Log value of Lactoferrin	6W	1.210	0.261	0.868	1.686
	6M	0.984	0.931	0.676	1.432
Log value of total proteins	6W	0.827	0.412	0.526	1.301
	6M	0.960	0.865	0.601	1.534
Year 3					
Log value of sIgA	6W	0.923	0.706	0.608	1.401
	6M	0.672	0.011	0.496	0.912
Log value of Lysozyme	6W	0.778	0.146	0.555	1.091
	6M	1.124	0.485	0.810	1.560
Log value of Lactoferrin	6W	0.778	0.156	0.551	1.100
	6M	1.072	0.736	0.714	1.610
Log value of total proteins	6W	1.039	0.879	0.633	1.706
	6M	1.163	0.575	0.685	1.976